A clinical-stage biotech engineering one-time gene therapies to hold back - and in some cases reverse - the retinal diseases that steal human sight.
There is a particular cruelty to inherited retinal disease. It often arrives in childhood, announces itself as trouble seeing at night, and then narrows the visual world year by year until a person is left staring through a keyhole. For X-linked retinitis pigmentosa - the disease at the center of Beacon Therapeutics' work - the patients are usually boys and young men, and for most of medical history there has been nothing to offer them but a diagnosis.
Beacon Therapeutics exists to change that arithmetic. The company is a clinical-stage ophthalmic gene therapy business, founded in 2023, that uses adeno-associated virus (AAV) vectors to deliver working copies of genes directly into the retina. The premise is deceptively simple: many blinding retinal conditions trace back to a single faulty gene. Deliver a functional copy to the right cells, once, and you may be able to slow or halt the loss of vision for years.
What makes Beacon notable is not a single molecule but the way it was assembled. In 2022, the life-sciences company builder Syncona took the struggling US biotech Applied Genetic Technologies Corp (AGTC) private, inheriting a late-stage program for retinitis pigmentosa. Syncona then combined that asset with complementary science from the University of Oxford and elsewhere, and in June 2023 launched Beacon with roughly $120 million. It was, in effect, a second act - a company built from proven parts rather than a blank-page startup.
Inherited and age-related retinal diseases - retinitis pigmentosa, cone-rod dystrophy, dry AMD - progressively destroy the light-sensing cells of the eye. Most have no approved treatment. Beacon targets the genetic cause, not just the symptoms.
Beacon packages a therapeutic gene inside an engineered adeno-associated virus and injects it into the eye. The vector ferries a working gene into retinal cells, aiming for durable, potentially one-time correction rather than lifelong dosing.
Its lead therapy serves boys and young men with X-linked retinitis pigmentosa, a rare disease. But its pipeline reaches toward geographic atrophy in dry AMD, which affects millions - a deliberate rare-to-prevalent strategy.
"This validates our strategy to save and restore sight for people living with rare and prevalent ocular diseases."
Beacon's lead candidate carries an unwieldy scientific name - laruparetigene zovaparvovec - mercifully shortened to laru-zova, and formerly known as AGTC-501. It is a gene therapy for X-linked retinitis pigmentosa, which is caused by mutations in the RPGR gene sitting on the X chromosome. That location is why the disease strikes males: they carry only one copy of the gene.
Laru-zova delivers a full-length, functional RPGR gene to the retina via a single subretinal injection. The goal is to restore the protein that photoreceptors need to survive, slowing or halting the relentless narrowing of the visual field.
The clinical evidence has been building steadily. In its Phase 2 DAWN trial, Beacon reported that laru-zova was generally well tolerated through 12 months, with sustained improvements in measures such as low-luminance visual acuity and macular sensitivity, presented at the ARVO 2026 meeting. Longer-term Phase 2 SKYLINE data extended to 36 months.
The decisive test is the registrational Phase 2/3 VISTA trial. Beacon completed enrollment in June 2025 and expects topline data in the second half of 2026 - the readout that could carry laru-zova toward regulatory approval and commercialization.
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Laru-zova (AGTC-501) | X-linked retinitis pigmentosa (XLRP) | AAV / RPGR gene | Registrational P2/3 |
| Dry AMD program | Geographic atrophy | AAV gene therapy | Preclinical |
| CRD program | Cone-rod dystrophy | AAV (Oxford-licensed) | Preclinical |
| Undisclosed asset | Retinal disease | AAV gene therapy | Early |
Table compiled from Beacon Therapeutics disclosures and press releases, 2023–2026. Stages approximate.
Capital, not just chemistry, is what carries a gene therapy across the finish line. Beacon has raised in escalating rounds, each stacked with specialist life-science investors - and, most recently, a blue-chip name.
The 2026 Series C, over $75 million and oversubscribed, was led by Life Sciences at Goldman Sachs Alternatives, with new backer the Retinal Degeneration Fund joining existing investors Syncona, Forbion, Oxford Science Enterprises and Advent Life Sciences. Total reported funding sits north of $500 million.
The eye is small, immune-privileged, and contained. A tiny dose of vector can reach the entire retina, and one eye can be treated while the other serves as a control. That makes ocular indications a favored proving ground for AAV medicine - and Beacon is built entirely around it.
Beacon's leadership includes people who helped bring earlier eye therapies to patients - from Luxturna to Nightstar and Gyroscope. In deep biotech, teams are the compounding asset; the science tends to follow the scientists.
Rather than staking everything on one molecule, Beacon runs four programs spanning rare and prevalent disease. Rare XLRP can fund and validate the platform; prevalent dry AMD is the larger prize.
By acquiring AGTC's late-stage program and in-licensing Oxford research, Beacon began its life with clinical data already in hand - years ahead of a from-scratch startup.
Beacon competes in a crowded ocular gene therapy field that includes MeiraGTx and Janssen (also pursuing XLRP), 4D Molecular Therapeutics, Atsena, Adverum, REGENXBIO and the legacy of Spark's Luxturna. Its differentiation rests on the maturity of laru-zova's data and the breadth of a pipeline aimed at both rare and mass-market retinal disease.
Beacon is a venture-backed, pre-commercial biopharmaceutical business. It deploys private capital to move AAV therapies through clinical trials and toward regulatory approval, with value created by de-risking assets step by step. Revenue would come from product sales, partnerships or acquisition once a therapy is approved. Today the customers, in a near-term sense, are the trial investigators, regulators and payers who determine whether a therapy reaches the market; ultimately, they are the patients and retinal surgeons who would use it.
Syncona takes Applied Genetic Technologies Corp private, securing its late-stage XLRP program as the seed for a new company.
Debuts with roughly $120M, combining AGTC's assets with University of Oxford science to pursue ocular gene therapies.
Forbion leads a Series B to push laru-zova through late-stage trials and advance preclinical programs.
Beacon finishes enrolling its registrational Phase 2/3 VISTA trial and reports positive interim DAWN and SKYLINE data.
Closes a $75M+ Series C led by Goldman Sachs Alternatives; presents positive 12-month DAWN data and awaits VISTA topline in H2 2026.
It develops AAV-based gene therapies to preserve and restore vision in people with rare and prevalent retinal diseases that cause blindness, led by a treatment for X-linked retinitis pigmentosa.
Laru-zova (laruparetigene zovaparvovec, formerly AGTC-501) is Beacon's lead gene therapy that delivers a functional copy of the RPGR gene to the retina to treat X-linked retinitis pigmentosa.
The company has roots in Alachua, Florida (from AGTC) and operations linked to London and the University of Oxford in the United Kingdom.
Beacon has raised over $500M across its 2023 launch (~$120M), a 2024 Series B ($170M) and an oversubscribed 2026 Series C (over $75M).
Beacon completed enrollment in its registrational Phase 2/3 VISTA trial in June 2025 and expects topline data in the second half of 2026.